Abramson Cancer Center University of Pennsylvania
Welcome,         Profile    Billing    Logout  
 7 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nayak, Lakshmi
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04906096: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Hourglass Jan 2024 - Jun 2024 : Last-patient-in of P2 trial for primary CNS lymphoma
Hourglass Jul 2022 - Dec 2022 : Initial interim data from trial for primary CNS lymphoma
Recruiting
2
25
US
PAXALISIB, GDC-0084
Lakshmi Nayak, MD, Kazia Therapeutics Limited
Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
12/25
12/26
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
12/25
01/26
NCT06475235: Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Recruiting
1
15
US
Pembrolizumab, Keytruda, MK-3475, Humanized X PD-1 mAb (H409A11) IgG4, Methotrexate, MTX, Temozolomide, Temodar, Temodal, Rituximab, Riabni, Rituxan, Ruxience, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Lymphoma, Primary Central Nervous System Lymphoma
06/25
06/27
Aregawi, Dawit G
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
02/26
03/26
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
Donthireddy, Vijayalakshmi
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
Nasta, Sunita
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
ANTLER, NCT04637763: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Recruiting
1
72
US, RoW
CB-010, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
08/25
09/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nayak, Lakshmi
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
NCT04906096: Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Hourglass Jan 2024 - Jun 2024 : Last-patient-in of P2 trial for primary CNS lymphoma
Hourglass Jul 2022 - Dec 2022 : Initial interim data from trial for primary CNS lymphoma
Recruiting
2
25
US
PAXALISIB, GDC-0084
Lakshmi Nayak, MD, Kazia Therapeutics Limited
Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
12/25
12/26
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
NCT04421560: Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Recruiting
1/2
37
US
Ibrutinib, Imbruvica, Pembrolizumab, Keytruda, Rituximab, Rituxan, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
12/25
01/26
NCT06475235: Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Recruiting
1
15
US
Pembrolizumab, Keytruda, MK-3475, Humanized X PD-1 mAb (H409A11) IgG4, Methotrexate, MTX, Temozolomide, Temodar, Temodal, Rituximab, Riabni, Rituxan, Ruxience, Truxima
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Lymphoma, Primary Central Nervous System Lymphoma
06/25
06/27
Aregawi, Dawit G
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
02/26
03/26
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
Donthireddy, Vijayalakshmi
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
Nasta, Sunita
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
ANTLER, NCT04637763: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Recruiting
1
72
US, RoW
CB-010, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
08/25
09/25

Download Options